Eton Pharmaceuticals Inc (ETON)vsZoetis Inc (ZTS)
ETON
Eton Pharmaceuticals Inc
$55.62
+0.47%
HEALTHCARE · Cap: $1.65B
ZTS
Zoetis Inc
$69.69
+0.85%
HEALTHCARE · Cap: $28.80B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 8920% more annual revenue ($9.53B vs $105.59M). ZTS leads profitability with a 27.7% profit margin vs 12.0%. ZTS trades at a lower P/E of 11.4x. ZTS earns a higher WallStSmart Score of 58/100 (C).
ETON
Buy52
out of 100
Grade: C-
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ETON.
Margin of Safety
+10.8%
Fair Value
$144.17
Current Price
$69.69
$74.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.8%
Revenue surging 98.6% year-over-year
Attractively priced relative to earnings
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 33.7x book value
ROE of -4.8% — below average capital efficiency
Trading at 8.9x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ETON
The strongest argument for ETON centers on Operating Margin, Revenue Growth. Revenue growth of 98.6% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : ETON
The primary concerns for ETON are Market Cap, P/E Ratio, Price/Book. A P/E of 147.9x leaves little room for execution misses.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
ETON profiles as a growth stock while ZTS is a declining play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.90 — expect wider price swings.
ETON is growing revenue faster at 98.6% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 52/100), backed by strong 27.7% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?